Cheol Kwak

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3347124/publications.pdf

Version: 2024-02-01

207	3,201	159585	289244
papers	citations	30	40
		h-index	g-index

209	209	209	4748
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Establishment of Prospective Registry of Active Surveillance for Prostate Cancer: The Korean Urological Oncology Society Database. World Journal of Men?s Health, 2023, 41, 110.	3.3	1
2	Efficacy of the Treatment of Intraperitoneal Bladder Perforation during Transurethral Resection of Bladder Tumor with the Urethral Catheter Alone: Retrospective Analysis of over 15 Years Using the Clinical Data Warehouse System. Urologia Internationalis, 2022, 106, 138-146.	1.3	4
3	Next-generation Proteomics-Based Discovery, Verification, and Validation of Urine Biomarkers for Bladder Cancer Diagnosis. Cancer Research and Treatment, 2022, 54, 882-893.	3.0	10
4	Immunotherapy for prostate cancer: Requirements for a successful regime transfer. Investigative and Clinical Urology, 2022, 63, 3.	2.0	8
5	Isolation and Genomic Analysis of Single Circulating Tumor Cell Using Human Telomerase Reverse Transcriptase and Desmogleinâ€2. Small Methods, 2022, , 2100938.	8.6	1
6	Geriatric assessment using the G8 to predict postoperative complications in patients undergoing major uro-oncologic surgery: Comparison with the Charlson Comorbidity Index. Journal of Geriatric Oncology, 2022, 13, 426-431.	1.0	4
7	De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase) as a Significant Prognostic Factor With Upper Urinary Tract Carcinoma Who Underwent Radical Nephroureterectomy and Adjuvant Chemotherapy. The Korean Journal of Urological Oncology, 2022, 20, 34-42.	0.1	0
8	Safety and feasibility of synchronous unilateral nephrectomy and contralateral heminephrectomy for extremely severe autosomal dominant polycystic kidney disease: Techniques and outcome. Investigative and Clinical Urology, 2022, 63, .	2.0	0
9	Isolation and Genomic Analysis of Single Circulating Tumor Cell Using Human Telomerase Reverse Transcriptase and Desmogleinâ€2 (Small Methods 4/2022). Small Methods, 2022, 6, .	8.6	0
10	Clinical determinants of recurrence in pTa bladder cancer following transurethral resection of bladder tumor. BMC Cancer, 2022, 22, .	2.6	6
11	Fumarate modulates phospholipase A2 receptor autoimmunity-induced podocyte injury in membranous nephropathy. Kidney International, 2021, 99, 443-455.	5.2	18
12	Impact of short warm ischemic time on longitudinal kidney function and survival rate after partial nephrectomy for renal cell carcinoma in patients with pre-existing chronic kidney disease stage III: A multi-institutional propensity score-matched study. European Journal of Surgical Oncology, 2021, 47, 470-476.	1.0	4
13	Metastatic renal cell carcinoma to the pancreas: Clinical features and treatment outcome. Journal of Surgical Oncology, 2021, 123, 204-213.	1.7	18
14	The clinical impact of strict criteria for active surveillance of prostate cancer in Korean population: Results from a prospective cohort. Investigative and Clinical Urology, 2021, 62, 430-437.	2.0	3
15	Stratifying risk for multiple, recurrent, and large (â‰¥3 cm) Ta, G1/G2 tumors in non-muscle-invasive bladder cancer. Investigative and Clinical Urology, 2021, 62, 408-415.	2.0	4
16	A comparison of the survival outcomes of robotic-assisted radical prostatectomy and radiation therapy in patients over 75 years old with non-metastatic prostate cancer: A Korean multicenter study. Investigative and Clinical Urology, 2021, 62, 535.	2.0	3
17	Targeted therapy response in early versus late recurrence of renal cell carcinoma after surgical treatment: A propensity scoreâ€matched study using the Korean Renal Cancer Study Group database. International Journal of Urology, 2021, 28, 417-423.	1.0	3
18	Comprehensive metabolomic profiling in early IgA nephropathy patients reveals urine glycine as a prognostic biomarker. Journal of Cellular and Molecular Medicine, 2021, 25, 5177-5190.	3.6	15

#	Article	IF	Citations
19	A Retrospective, Multicenter, Long-Term Follow-Up Analysis of the Prognostic Characteristics of Recurring Non-Metastatic Renal Cell Carcinoma After Partial or Radical Nephrectomy. Frontiers in Oncology, 2021, 11, 653002.	2.8	4
20	PDLIM2 Suppression Inhibit Proliferation and Metastasis in Kidney Cancer. Cancers, 2021, 13, 2991.	3.7	4
21	Pyuria as a Predictive Marker of Bacillus Calmetteâ€“GuÃ©rin Unresponsiveness in Non-Muscle Invasive Bladder Cancer. Journal of Clinical Medicine, 2021, 10, 3764.	2.4	5
22	Investigation of Information Acquisition Channel for Prostate Cancer High-Risk Group. The Korean Journal of Urological Oncology, 2021, 19, 174-182.	0.1	1
23	Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma. Medicine (United States), 2021, 100, e26826.	1.0	2
24	Machine learning-based prediction of acute kidney injury after nephrectomy in patients with renal cell carcinoma. Scientific Reports, 2021, 11, 15704.	3.3	12
25	Estimated Glomerular Filtration Rate as a Prognostic Factor in Urothelial Carcinoma of the Upper Urinary Tract: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 4155.	2.4	2
26	Prostate-specific membrane antigen-mediated theragnostics in prostate cancer. Investigative and Clinical Urology, 2021, 62, 497.	2.0	4
27	Prognostic Impact of Preoperative Renal Insufficiency on Metastasis-Free Survival after Radical Cystectomy. Journal of Cancer, 2021, 12, 7320-7325.	2.5	1
28	Acidic Urine Is Associated With Poor Prognosis of Upper Tract Urothelial Carcinoma. Frontiers in Oncology, 2021, 11, 817781.	2.8	1
29	Establishment of Novel Intraoperative Monitoring and Mapping Method for the Cavernous Nerve During Robot-assisted Radical Prostatectomy: Results of the Phase I/II, First-in-human, Feasibility Study. European Urology, 2020, 78, 221-228.	1.9	10
30	Korean version of the G-8 geriatric screening tool: Translation and linguistic validation. Journal of Geriatric Oncology, 2020, 11, 470-474.	1.0	3
31	The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 187-196.	2.5	24
32	Patients with Biopsy Gleason Score 3 + 4 Are Not Appropriate Candidates for Active Surveillance. Urologia Internationalis, 2020, 104, 199-204.	1.3	4
33	Scale-Up Evaluation of a Composite Tumor Marker Assay for the Early Detection of Renal Cell Carcinoma. Diagnostics, 2020, 10, 750.	2.6	6
34	The prognostic role of preoperative serum albumin/globulin ratio in patients with non-metastatic renal cell carcinoma undergoing partial or radical nephrectomy. Scientific Reports, 2020, 10, 11999.	3.3	15
35	Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial. BMJ Open, 2020, 10, e035530.	1.9	3
36	Role of multiparametric magnetic resonance imaging to predict postoperative Gleason score upgrading in prostate cancer with Gleason score 3â€‰+â€‰4. World Journal of Urology, 2020, 39, 1825-1830.	2.2	6

#	Article	IF	Citations
37	Histone Demethylase LSD1 Regulates Kidney Cancer Progression by Modulating Androgen Receptor Activity. International Journal of Molecular Sciences, 2020, 21, 6089.	4.1	21
38	Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 5658.	4.1	15
39	Sharing the initial experience of pan-cancer panel analysis in high-risk renal cell carcinoma in the Korean population. BMC Urology, 2020, 20, 125.	1.4	6
40	Crosstalk between Prostate Cancer Cells and Tumor-Associated Fibroblasts Enhances the Malignancy by Inhibiting the Tumor Suppressor PLZF. Cancers, 2020, 12, 1083.	3.7	3
41	Intraoperative allogeneic blood transfusion is associated with adverse oncological outcomes in patients with surgically treated non-metastatic clear cell renal cell carcinoma. International Journal of Clinical Oncology, 2020, 25, 1551-1561.	2.2	4
42	Korean version of the convalescence and recovery evaluation: translation and linguistic validation. Prostate International, 2020, 8, 158-166.	2.3	1
43	Survival Benefits Based on the Number of Lymph Nodes Removed during Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2020, 9, 1933.	2.4	7
44	Differences in risk factors for biochemical recurrence after radical prostatectomy stratified by the degree of obesity: Focused on surgical methods. Scientific Reports, 2020, 10, 10157.	3.3	3
45	Robust Association between Acute Kidney Injury after Radical Nephrectomy and Long-term Renal Function. Journal of Clinical Medicine, 2020, 9, 619.	2.4	8
46	The number of metabolic features as a significant prognostic factor in patients with metastatic renal cell carcinoma. Scientific Reports, 2020, 10, 6967.	3.3	3
47	Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting. Investigative and Clinical Urology, 2020, 61, 19.	2.0	6
48	Targeted next-generation sequencing for locally advanced prostate cancer in the Korean population. Investigative and Clinical Urology, 2020, 61, 127.	2.0	8
49	Impact of perioperative blood transfusion on oncologic outcomes in patients with nonmetastatic renal cell carcinoma treated with curative nephrectomy: A retrospective analysis of a large, single-institutional cohort. Investigative and Clinical Urology, 2020, 61, 136.	2.0	6
50	Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database. Investigative and Clinical Urology, 2020, 61, 260.	2.0	5
51	Long-term oncologic outcomes after radical prostatectomy in clinically localized prostate cancer: 10-year follow-up in Korea. Investigative and Clinical Urology, 2020, 61, 269.	2.0	7
52	The platelet-to-lymphocyte ratio as a significant prognostic factor to predict survival outcomes in patients with synchronous metastatic renal cell carcinoma. Investigative and Clinical Urology, 2020, 61, 475.	2.0	7
53	Survival benefit of neoadjuvant chemotherapy in pathologic T2N0 or lower urothelial carcinoma patients: evidence to support the use of neoadjuvant chemotherapy. Translational Andrology and Urology, 2020, 9, 1270-1277.	1.4	1
54	MLL5, a histone modifying enzyme, regulates androgen receptor activity in prostate cancer cells by recruiting co-regulators, HCF1 and SET1. BMB Reports, 2020, 53, 634-639.	2.4	5

#	Article	IF	Citations
55	Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data. Annals of Translational Medicine, 2020, 8, 1389.	1.7	0
56	Clinical outcomes and costs of robotic surgery in prostate cancer: a multiinstitutional study in Korea. Prostate International, 2019, 7, 19-24.	2.3	14
57	Adjuvant Treatments for Advanced Stage, Non-metastatic Upper Tract Urothelial Carcinoma: A Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2019, 104, 819-827.	0.8	12
58	Intravesical Chemotherapy after Radical Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma: A Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine, 2019, 8, 1059.	2.4	11
59	Prostate specific antigen (PSA) persistence 6 weeks after radical prostatectomy and pelvic lymph node dissection as predictive factor of radiographic progression in node-positive prostate cancer patients. Journal of Cancer, 2019, 10, 2237-2242.	2.5	15
60	Retrospective Multicenter Long-Term Follow-up Analysis of Prognostic Risk Factors for Recurrence-Free, Metastasis-Free, Cancer-Specific, and Overall Survival After Curative Nephrectomy in Non-metastatic Renal Cell Carcinoma. Frontiers in Oncology, 2019, 9, 859.	2.8	25
61	Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification. BMC Cancer, 2019, 19, 897.	2.6	14
62	Late Recurrence of Bladder Cancer following Radical Cystectomy: Characteristics and Outcomes. Urologia Internationalis, 2019, 103, 291-296.	1.3	8
63	De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase) as a Significant Prognostic Factor in Patients Undergoing Radical Cystectomy with Bladder Urothelial Carcinoma: A Propensity Score-Matched Study. Disease Markers, 2019, 2019, 1-8.	1.3	18
64	The association between intraoperative urine output and postoperative acute kidney injury differs between partial and radical nephrectomy. Scientific Reports, 2019, 9, 760.	3.3	9
65	The Cancer of the Bladder Risk Assessment (COBRA) score for predicting cancer-specific survival after radical cystectomy for urothelial carcinoma of the bladder: External validation in a cohort of Korean patients. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 470-477.	1.6	4
66	Association Between Preoperative Hydronephrosis and Prognosis After Radical Cystectomy Among Patients With Bladder Cancer: A Systemic Review and Meta-Analysis. Frontiers in Oncology, 2019, 9, 158.	2.8	13
67	The Efficacy of Lymph Node Embolization Using N-Butyl Cyanoacrylate Compared to Ethanol Sclerotherapy in the Management of Symptomatic Lymphorrhea after Pelvic Surgery. Journal of Vascular and Interventional Radiology, 2019, 30, 195-202.e1.	0.5	31
68	Does reduced E-cadherin expression correlate with poor prognosis in patients with upper tract urothelial cell carcinoma?. Medicine (United States), 2019, 98, e17377.	1.0	0
69	Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy: results from retrospective, multicenter data. Prostate Cancer and Prostatic Diseases, 2019, 22, 150-158.	3.9	6
70	Effects of Variant Histology on the Oncologic Outcomes of Patients With Upper Urinary Tract Carcinoma After Radical Nephroureterectomy: A Propensity Scoreâ€“Matched Analysis. Clinical Genitourinary Cancer, 2019, 17, e394-e407.	1.9	14
71	Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system. World Journal of Urology, 2019, 37, 1867-1877.	2.2	24
72	Genderâ€•and cholesterolâ€specific predictive value of body mass index in renal cell carcinoma: A multicenter study. Asia-Pacific Journal of Clinical Oncology, 2019, 15, e36-e42.	1.1	2

#	Article	IF	Citations
73	Establishment of the Seoul National University Prospectively Enrolled Registry for Genitourinary Cancer (SUPER-GUC): A prospective, multidisciplinary, bio-bank linked cohort and research platform. Investigative and Clinical Urology, 2019, 60, 235.	2.0	25
74	Trends in clinical, operative, and pathologic characteristics of surgically treated renal mass in a Korean center: A surgical series from 1988 through 2015. Investigative and Clinical Urology, 2019, 60, 184.	2.0	2
75	Is Primary Androgen Deprivation Therapy a Suitable Option for Asian Patients With Prostate Cancer Compared With Radical Prostatectomy?. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 441-449.	4.9	1
76	Predictors for the detection of prostate cancer and clinically significant prostate cancer using TRUS-guided biopsy in patients with negative initial biopsy results. World Journal of Urology, 2018, 36, 1047-1053.	2.2	1
77	Ki-67 as a Prognostic Marker in Upper Urinary Tract Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Clinical Genitourinary Cancer, 2018, 16, e831-e841.	1.9	13
78	Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study. Urology, 2018, 111, 145-150.	1.0	5
79	Sex-Specific Prognostic Significance of Obesity in Nonmetastatic Clear-Cell Renal-Cell Carcinoma in Korea: A Large Multicenter Cohort Analysis. Clinical Genitourinary Cancer, 2018, 16, e173-e179.	1.9	7
80	Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib. Journal of Korean Medical Science, 2018, 33, e325.	2.5	13
81	Should intravesical Bacillus Calmetteâ€“Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?. PLoS ONE, 2018, 13, e0208267.	2.5	7
82	Partial versus Radical Nephrectomy for T1-T2 Renal Cell Carcinoma in Patients with Chronic Kidney Disease Stage III: a Multiinstitutional Analysis of Kidney Function and Survival Rate. Journal of Korean Medical Science, 2018, 33, e277.	2.5	7
83	Prognostic Impact of Nutritional Status Assessed by the Controlling Nutritional Status (CONUT) Score in Patients with Surgically Treated Renal Cell Carcinoma. Nutrition and Cancer, 2018, 70, 886-894.	2.0	18
84	Differences in Pathologic Results of Repeat Transurethral Resection of Bladder Tumor (TURBT) according to Institution Performing the Initial TURBT: Comparative Analyses between Referred and Nonreferred Group. BioMed Research International, 2018, 2018, 1-7.	1.9	6
85	Comparison of Renal Function after Radical Surgery for Upper Tract Urothelial Carcinoma versus Renal Cell Carcinoma: Propensity Score Matching. Urologia Internationalis, 2018, 101, 400-408.	1.3	3
86	Lymphovascular invasion have a similar prognostic value as lymph node involvement in patients undergoing radical cystectomy with urothelial carcinoma. Scientific Reports, 2018, 8, 15928.	3.3	9
87	Rate and association of lower urinary tract infection with recurrence after transurethral resection of bladder tumor. Investigative and Clinical Urology, 2018, 59, 10.	2.0	14
88	Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer. International Journal of Cancer, 2018, 143, 2849-2861.	5.1	37
89	The Impact of Pathologic Upgrading of Gleason Score 7 Prostate Cancer on the Risk of the Biochemical Recurrence after Radical Prostatectomy. BioMed Research International, 2018, 2018, 1-6.	1.9	7
90	Ageâ€dependent prognostic value of body mass index for nonâ€metastatic clear cell renal cell carcinoma: A large multicenter retrospective analysis. Journal of Surgical Oncology, 2018, 118, 199-205.	1.7	9

#	Article	IF	Citations
91	Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy. Journal of Urology, 2018, 200, 989-995.	0.4	16
92	Comparison of intraoperative handling and wound healing between (NEOSORBÂ® plus) and coated polyglactin 910 suture (NEOSORBÂ®): a prospective, single-blind, randomized controlled trial. BMC Surgery, 2018, 18, 45.	1.3	7
93	Outcomes of pathologic stage T3a renal cell carcinoma up-staged from small renal tumor: emphasis on partial nephrectomy. BMC Cancer, 2018, 18, 427.	2.6	31
94	Psychometric validation study of the Korean version of the Functional Assessment of Cancer Therapy-Vanderbilt Cystectomy Index. PLoS ONE, 2018, 13, e0190570.	2.5	1
95	Comparisons of oncological outcomes and perioperative complications between laparoscopic and open radical nephrectomies in patients with clinical T2 renal cell carcinoma (â‰¥7cm). PLoS ONE, 2018, 13, e0191786.	2.5	4
96	Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Non-muscle Invasive Bladder Cancer Patients: Initial Intravesical Bacillus Calmette-Guerin Treatment After Transurethral Resection of Bladder Tumor Setting. Frontiers in Oncology, 2018, 8, 642.	2.8	21
97	Selection Criteria for Active Surveillance of Patients with Prostate Cancer in Korea: A Multicenter Analysis of Pathology after Radical Prostatectomy. Cancer Research and Treatment, 2018, 50, 265-274.	3.0	10
98	Effects of Aspirin, Nonsteroidal Anti-inflammatory Drugs, Statin, and COX2 Inhibitor on the Developments of Urological Malignancies: A Population-Based Study with 10-Year Follow-up Data in Korea. Cancer Research and Treatment, 2018, 50, 984-991.	3.0	19
99	Comprehensive genetic characterization of TFE3-positive renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 635-635.	1.6	0
100	De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study. BJU International, 2017, 119, 261-267.	2.5	53
101	Surgical treatment of renal cell carcinoma: Can morphological features of inferior vena cava tumor thrombus on computed tomography or magnetic resonance imaging be a prognostic factor?. International Journal of Urology, 2017, 24, 102-109.	1.0	11
102	Prognostic Role of Neutrophil-to-lymphocyte Ratio-based Markers During Pre- and Postadjuvant Chemotherapy in Patients With Advanced Urothelial Carcinoma of Upper Urinary Tract. Clinical Genitourinary Cancer, 2017, 15, e633-e643.	1.9	6
103	Extended versus Standard Pelvic Lymph Node Dissection in Radical Prostatectomy on Oncological and Functional Outcomes: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2017, 24, 2047-2054.	1.5	39
104	Can partial nephrectomy provide equal oncological efficiency and safety compared with radical nephrectomy in patients with renal cell carcinoma (â‰¥4 cm)? A propensity scoreâ€“matched study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 379-385.	1.6	36
105	Can the Preoperative Neutrophil-to-Lymphocyte Ratio Significantly Predict the Conditional Survival Probability in Muscle-invasive Bladder Cancer Patients Undergoing Radical Cystectomy?. Clinical Genitourinary Cancer, 2017, 15, e411-e420.	1.9	10
106	Comparison of bone mineral loss by combined androgen block agonist versus GnRH in patients with prostate cancer: A 12 month-prospective observational study. Scientific Reports, 2017, 7, 39562.	3.3	8
107	Prognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated nonâ€“muscle-invasive bladder cancer patients. Scientific Reports, 2017, 7, 1380.	3.3	5
108	The De Ritis (aspartate transaminase/alanine transaminase) ratio as a predictor of oncological outcomes in patients after surgery for upper urinary tract urothelial carcinoma. International Urology and Nephrology, 2017, 49, 1383-1390.	1.4	28

#	Article	IF	Citations
109	Progression to T1 High Grade (T1HG) from a Lower Stage/Grade is Associated with Poorer Survival Outcomes than Initial Diagnosis with T1HG Bladder Cancer. Annals of Surgical Oncology, 2017, 24, 2413-2419.	1.5	1
110	Clinicopathologic Characteristics and Prognosis of Xp11.2 Translocation Renal Cell Carcinoma: Multicenter, Propensity Score Matching Analysis. Clinical Genitourinary Cancer, 2017, 15, e819-e825.	1.9	14
111	Variant histology as a significant predictor of survival after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 458.e9-458.e15.	1.6	31
112	Preoperative Cholesterol Level Is Associated With Worse Pathological Outcomes and Postoperative Survival in Localized Renal Cell Carcinoma Patients: A Propensity Scoreâ€“Matched Study. Clinical Genitourinary Cancer, 2017, 15, e935-e941.	1.9	12
113	Roles of fluid shear stress and retinoic acid in the differentiation of primary cultured human podocytes. Experimental Cell Research, 2017, 354, 48-56.	2.6	28
114	Dose, duration and strain of bacillus Calmetteâ€“Guerin in the treatment of nonmuscle invasive bladder cancer. Medicine (United States), 2017, 96, e8300.	1.0	23
115	RNF20 Suppresses Tumorigenesis by Inhibiting the SREBP1c-PTTG1 Axis in Kidney Cancer. Molecular and Cellular Biology, 2017, 37, .	2.3	40
116	Impact of Gleason score on biochemical recurrence in patients with pT3aN0/Nx prostate cancer with positive surgical margins: a multicenter study from the Prostate Cancer Research Committee. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2393-2400.	2.5	5
117	Predictors for Intravesical Recurrence Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A National Multicenter Analysis. Clinical Genitourinary Cancer, 2017, 15, e1055-e1061.	1.9	26
118	Preoperative cholesterol level as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with cyto-reductive nephrectomy. BMC Cancer, 2017, 17, 364.	2.6	17
119	Clinical Significance of Subclassification of Papillary Renal Cell Carcinoma: Comparison of Clinicopathologic Parameters and Oncologic Outcomes Between Papillary Histologic Subtypes 1Âand 2 Using the Korean Renal Cell Carcinoma Database. Clinical Genitourinary Cancer, 2017, 15, e181-e186.	1.9	16
120	Concurrent Autophagy Inhibition Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human Bladder Cancer Cells. International Journal of Molecular Sciences, 2017, 18, 321.	4.1	25
121	Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study. BioMed Research International, 2017, 2017, 1-13.	1.9	4
122	Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) After Initial TUR-BT: Comparative Analyses with Noninvasive Low-Grade Papillary Urothelial Carcinoma (LGPUC). Journal of Cancer, 2017, 8, 2885-2891.	2.5	15
123	Concurrent treatment with simvastatin and NF-Î¹B inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-Î¹B/LIN28/let-7 miRNA signaling pathway. PLoS ONE, 2017, 12, e0184644.	2.5	31
124	Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer. PLoS ONE, 2017, 12, e0189354.	2.5	11
125	Establishment of Korean prostate cancer database by the Korean Urological Oncology Society. Investigative and Clinical Urology, 2017, 58, 434.	2.0	7
126	Predicting biochemical recurrence in patients with high-risk prostate cancer using the apparent diffusion coefficient of magnetic resonance imaging. Investigative and Clinical Urology, 2017, 58, 12.	2.0	15

#	Article	IF	Citations
127	Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor. Oncotarget, 2017, 8, 12891-12901.	1.8	49
128	Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials. Oncotarget, 2017, 8, 59690-59697.	1.8	20
129	Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials. Oncotarget, 2017, 8, 81204-81214.	1.8	23
130	Statin inhibits the proliferation of human castration-resistant prostate cancer cells by controlling NFkB-LIN28B-let7 miRNA signaling pathway.. Journal of Clinical Oncology, 2017, 35, 269-269.	1.6	1
131	Association between demographic factors and prognosis in urothelial carcinoma of the upper urinary tract: a systematic review and meta-analysis. Oncotarget, 2017, 8, 7464-7476.	1.8	28
132	Impact of preoperative thrombocytosis on prognosis after surgical treatment in pathological T1 and T2 renal cell carcinoma: results of a multi-institutional comprehensive study. Oncotarget, 2017, 8, 64449-64458.	1.8	6
133	Significance of Ki-67 in non-muscle invasive bladder cancer patients: a systematic review and meta-analysis. Oncotarget, 2017, 8, 100614-100630.	1.8	19
134	Histone demethylase KDM7a to control androgen receptor activity in hormone-sensitive prostate cancer.. Journal of Clinical Oncology, 2017, 35, 262-262.	1.6	0
135	The establishment of KORCC (KOrean Renal Cell Carcinoma) database. Investigative and Clinical Urology, 2016, 57, 50.	2.0	30
136	Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Nonmetastatic Renal Cell Carcinoma: A Large, Multicenter Cohort Analysis. BioMed Research International, 2016, 2016, 1-8.	1.9	20
137	Perioperative Blood Transfusion as a Significant Predictor of Biochemical Recurrence and Survival after Radical Prostatectomy in Patients with Prostate Cancer. PLoS ONE, 2016, 11, e0154918.	2.5	16
138	Pathological T3a Upstaging of Clinical T1 Renal Cell Carcinoma: Outcomes According to Surgical Technique and Predictors of Upstaging. PLoS ONE, 2016, 11, e0166183.	2.5	40
139	Impact of Young Age at Diagnosis on Survival in Patients with Surgically Treated Renal Cell Carcinoma: a Multicenter Study. Journal of Korean Medical Science, 2016, 31, 1976.	2.5	20
140	Renal cell carcinoma in endâ€stage renal disease: Multiâ€institutional comparative analysis of survival. International Journal of Urology, 2016, 23, 465-471.	1.0	10
141	PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castrationâ€resistant prostate cancerâ€like cells. Prostate, 2016, 76, 273-285.	2.3	20
142	Is lymphovascular invasion a powerful predictor for biochemical recurrence in pT3 N0 prostate cancer? Results from the K-CaP database. Scientific Reports, 2016, 6, 25419.	3.3	17
143	Efficacy of Partial Nephrectomy for Renal Tumors >4 cm: Comparison With Renal Tumors â‰¤4 cm. International Surgery, 2016, 101, 7-13.	0.1	0
144	Risk of metastasis for T1a renal cell carcinoma. World Journal of Urology, 2016, 34, 553-559.	2.2	32

#	Article	IF	Citations
145	Pathological T0 Following Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Network Meta-analysis. Clinical Cancer Research, 2016, 22, 1086-1094.	7.0	27
146	The Prognostic Significance of the Early Postoperative Neutrophil-to-Lymphocyte Ratio in Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. Annals of Surgical Oncology, 2016, 23, 335-342.	1.5	50
147	Single, immediate postoperative instillation of chemotherapy in non-muscle invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials using different drugs. Oncotarget, 2016, 7, 45479-45488.	1.8	29
148	Conditional Survival and Associated Prognostic Factors in Patients with Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy: A Retrospective Study at a Single Institution. Cancer Research and Treatment, 2016, 48, 621-631.	3.0	9
149	Quality-adjusted survival comparison between androgen deprivation with radiation therapy versus radiation therapy alone for locally advanced prostate cancer: Decision analysis from RTOG 85-31 trial.. Journal of Clinical Oncology, 2016, 34, 265-265.	1.6	0
150	The Characteristics of Recurrent Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy without Bladder Cuff Excision. Yonsei Medical Journal, 2015, 56, 375.	2.2	13
151	External Validation of Models for Prediction of Lymph Node Metastasis in Urothelial Carcinoma of the Bladder. PLoS ONE, 2015, 10, e0120552.	2.5	5
152	Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. PLoS ONE, 2015, 10, e0133371.	2.5	7
153	Survival Outcomes and Predictive Factors for Female Urethral Cancer: Long-term Experience with Korean Patients. Journal of Korean Medical Science, 2015, 30, 1143.	2.5	14
154	Prognostic Value of Body Mass Index According to Histologic Subtype in Nonmetastatic Renal Cell Carcinoma: A Large Cohort Analysis. Clinical Genitourinary Cancer, 2015, 13, 461-468.	1.9	19
155	The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma. Journal of Urology, 2015, 194, 1112-1119.	0.4	19
156	The prognostic impact of perioperative blood transfusion on survival in patients with bladder urothelial carcinoma treated with radical cystectomy. Korean Journal of Urology, 2015, 56, 295.	1.2	20
157	Extracapsular Extension of Pelvic Lymph Node Metastasis is an Independent Prognostic Factor in Bladder Cancer: A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2015, 22, 3745-3750.	1.5	27
158	Perioperative and long-term renal functional outcomes of robotic versus laparoscopic partial nephrectomy: a multicenter matched-pair comparison. World Journal of Urology, 2015, 33, 1579-1584.	2.2	38
159	Effect of Sex on Prognosis of Urothelial Carcinoma: Propensity Score Matching Analysis. Clinical Genitourinary Cancer, 2015, 13, e113-e121.	1.9	12
160	Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 203.e1-203.e9.	1.6	11
161	Diabetes Mellitus as an Independent Predictor of Survival of Patients Surgically Treated for Renal Cell Carcinoma: A Propensity Score Matching Study. Journal of Urology, 2015, 194, 1554-1560.	0.4	19
162	Are urothelial carcinomas of the upper urinary tract a distinct entity from urothelial carcinomas of the urinary bladder? Behavior of urothelial carcinoma after radical surgery with respect to anatomical location: a case control study. BMC Cancer, 2015, 15, 149.	2.6	15

#	Article	IF	Citations
163	Preoperative Chronic Kidney Disease Status is an Independent Prognostic Factor in Patients with Renal Cell Carcinoma. Annals of Surgical Oncology, 2015, 22, 4098-4103.	1.5	16
164	A propensity-matched comparison of perioperative complications and of chronic kidney disease between robot-assisted laparoscopic partial nephrectomy and radiofrequency ablative therapy. Asian Journal of Surgery, 2015, 38, 126-133.	0.4	9
165	Overall survival and renal function after partial and radical nephrectomy among older patients with localised renal cell carcinoma: A propensity-matched multicentre study. European Journal of Cancer, 2015, 51, 489-497.	2.8	38
166	Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis. BMC Cancer, 2015, 15, 447.	2.6	53
167	S100A3 Suppression Inhibits InÂVitro and InÂVivo Tumor Growth and Invasion of Human Castration-resistant Prostate Cancer Cells. Urology, 2015, 85, 273.e9-273.e15.	1.0	19
168	Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study. PLoS ONE, 2015, 10, e0135165.	2.5	5
169	Clinicohistological characteristics of renal cell carcinoma in children: A multicentre study. Canadian Urological Association Journal, 2015, 9, 705.	0.6	7
170	Differences in peritumoral pseudocapsule characteristics according to clinicopathological factors in clinical T1a renal tumors. International Journal of Clinical and Experimental Pathology, 2015, 8, 11323-31.	0.5	5
171	Pre- and Post-Operative Nomograms to Predict Recurrence-Free Probability in Korean Men with Clinically Localized Prostate Cancer. PLoS ONE, 2014, 9, e100053.	2.5	14
172	Inhibition of Autophagy Potentiates Atorvastatin-Induced Apoptotic Cell Death in Human Bladder Cancer Cells in Vitro. International Journal of Molecular Sciences, 2014, 15, 8106-8121.	4.1	39
173	Different methods of hilar clamping during partial nephrectomy: Impact on renal function. International Journal of Urology, 2014, 21, 232-236.	1.0	12
174	Abiraterone acetate and prednisolone for metastatic castrationâ€resistant prostate cancer failing androgen deprivation and docetaxelâ€based chemotherapy: A phaseâ€‰<scp>II</scp> bridging study in <scp>K</scp>orean and <scp>T</scp>aiwanese patients. International Journal of Urology, 2014, 21, 1239-1244.	1.0	11
175	Current Status of Renal Biopsy for Small Renal Masses. Korean Journal of Urology, 2014, 55, 568.	1.2	12
176	Reassessment of Prognostic Heterogeneity of pT3 Renal Pelvic Urothelial Carcinoma: Analysis in Terms of Proposed pT3 Subclassification Systems. Journal of Urology, 2014, 192, 1064-1071.	0.4	17
177	Cytotoxic Effects of Escin on Human Castration-resistant Prostate Cancer Cells Through the Induction of Apoptosis and G2/M Cell Cycle Arrest. Urology, 2014, 84, 982.e1-982.e7.	1.0	30
178	Risk Prediction Models of Locoregional Failure After Radical Cystectomy for Urothelial Carcinoma: External Validation in a Cohort of Korean Patients. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1032-1037.	0.8	23
179	Post-treatment neutrophil-to-lymphocyte ratio in predicting prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first line therapy. SpringerPlus, 2014, 3, 243.	1.2	31
180	External Validation of Online Predictive Models for Prediction of Cancer-specific Mortality and All-cause Mortality in Patients with Urothelial Carcinoma of the Urinary Bladder. Annals of Surgical Oncology, 2014, 21, 3132-3141.	1.5	14

#	Article	IF	Citations
181	A case of reninoma with variant angina. Kidney Research and Clinical Practice, 2014, 33, 106-108.	2.2	2
182	Effect of Gleason scores of lymph node metastases on prognosis of patients with prostate cancer. International Journal of Clinical and Experimental Pathology, 2014, 7, 6141-8.	0.5	2
183	Prognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy. Annals of Nuclear Medicine, 2013, 27, 748-755.	2.2	20
184	Simvastatin Induces Apoptosis in Castrate Resistant Prostate Cancer Cells by Deregulating Nuclear Factor-ÎºB Pathway. Journal of Urology, 2013, 189, 1547-1552.	0.4	34
185	Lymphovascular invasion as a prognostic factor in the upper urinary tract urothelial carcinoma: A systematic review and meta-analysis. European Journal of Cancer, 2013, 49, 2665-2680.	2.8	44
186	Extramammary Paget Disease of External Genitalia: Surgical Excision and Follow-up Experiences With 19 Patients. Korean Journal of Urology, 2013, 54, 834.	1.2	14
187	Influence of nutritional deficiency on prognosis of renal cell carcinoma (<scp>RCC</scp>). BJU International, 2013, 112, 775-780.	2.5	38
188	Impact of Prostate Volume on Oncological and Functional Outcomes After Radical Prostatectomy: Robot-Assisted Laparoscopic Versus Open Retropubic. Korean Journal of Urology, 2013, 54, 15.	1.2	23
189	Predictive value of ribonucleotide reductase regulatory subunit M1 (RRM1) and excision cross-complementing-1 (ERCC1) in advanced urothelial carcinoma (UC) treated with first-line gemcitabine (G) and platinum (P)-based chemotherapy (CT).. Journal of Clinical Oncology, 2013, 31, e15614-e15614.	1.6	0
190	Nomograms to predict the pathological stage of clinically localized prostate cancer in Korean men: Comparison with Western predictive tools using decision curve analysis. International Journal of Urology, 2012, 19, 846-852.	1.0	24
191	Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis. BJU International, 2012, 110, E553-8.	2.5	65
192	Is there a Role of the Histologic Subtypes of Papillary Renal Cell Carcinoma as a Prognostic Factor?. Japanese Journal of Clinical Oncology, 2009, 39, 664-670.	1.3	18
193	Chronic pulmonary disease negatively influences the prognosis of patients with advanced prostate cancer. World Journal of Urology, 2009, 27, 643-652.	2.2	5
194	Young Age Is Independent Prognostic Factor for Cancer-Specific Survival of Low-Stage Clear Cell Renal Cell Carcinoma. Urology, 2009, 73, 137-141.	1.0	37
195	Prostate Specific Antigen Half-Time and Prostate Specific Antigen Doubling Time as Predictors of Response to Androgen Deprivation Therapy for Metastatic Prostate Cancer. Journal of Urology, 2009, 181, 2520-2525.	0.4	36
196	No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 310-316.	1.6	14
197	Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. Journal of Surgical Oncology, 2007, 95, 317-323.	1.7	46
198	Prevention of nephrolithiasis by Lactobacillus in stone-forming rats: a preliminary study. Urological Research, 2006, 34, 265-270.	1.5	28

#	Article	IF	Citations
199	Effective local control of prostate cancer by intratumoral injection of 166Ho-chitosan complex (DW-166HC) in rats. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1400-1405.	6.4	14
200	Effect of circumcision on urinary tract infection after successful antireflux surgery. BJU International, 2004, 94, 627-629.	2.5	37
201	Initial Tumor Stage and Grade as a Predictive Factor for Recurrence in Patients With Stage T1 Grade 3 Bladder Cancer. Journal of Urology, 2004, 171, 149-152.	0.4	43
202	Urinary Oxalate Levels and the Enteric Bacterium Oxalobacter formigenes in Patients with Calcium Oxalate Urolithiasis. European Urology, 2003, 44, 475-481.	1.9	75
203	Molecular Epidemiology of FecalOxalobacter formigenesin Healthy Adults Living in Seoul, Korea. Journal of Endourology, 2003, 17, 239-243.	2.1	14
204	Prognostic Significance of The Nadir Prostate Specific Antigen Level After Hormone Therapy for Prostate Cancer. Journal of Urology, 2002, 168, 995-1000.	0.4	105
205	Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. Journal of Urology, 2002, 168, 995-1000.	0.4	66
206	Phase I Clinical Trial of Prostate-Specific Membrane Antigen-Targeting ⁶⁸Ga-NGUL PET/CT in Healthy Volunteers and Patients with Prostate Cancer. Korean Journal of Radiology, 0, 23, .	3.4	2
207	High Carbohydrate Antigen 19-9 Levels Indicate Poor Prognosis of Upper Tract Urothelial Carcinoma. Frontiers in Oncology, 0, 12, .	2.8	0